Please login to the form below
DiCE Molecules
This page shows the latest DiCE Molecules news and features for those working in and with pharma, biotech and healthcare.
Sanofi bets on DiCE to find oral alternatives to injectable drugs
Sanofi has made a small-molecule discovery engine developed by US biotech DiCE Molecules a core part of its R&D portfolio. ... DiCE's approach to drug discovery focuses on targeting protein-protein interactions that to date have only been addressed with
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2016
Acquisition – division. $5, 869. DiCE Molecules/ Sanofi. Technology platform to select and optimise drug-like ligands targeting a range of therapeutic areas. ... Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
DiCE Molecules adds Dr Richard Scheller to its board of directors
He currently serves as chief scientific officer at 23andMe. San Francisco-based DiCE Molecules has appointed Dr Richard Scheller to its board of directors. ... Dr Scheller brings nearly 20 years of leadership in drug discovery research and development to
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
